Technologies available from Fred Hutch

Highlight 1

Muscular Dystrophy (FSHD) TargetsThe identification of genes and proteins that damage muscle cells and the mechanisms that cause facioscapulohumeral muscular dystrophy (FSHD), the third most common form of inherited muscular dystrophy, provides a foundation for development of first-in-class therapeutics and biomarker based diagnostic tests.Learn more>

Highlight 2

New Class of Drug Leads Fred Hutch scientists are developing a new class of drug scaffolds capable of targeting protein-protein interactions. These proprietary drug leads may act as targeting agents for specific imaging and therapeutic applications.Learn more>

Highlight 3

Accurate, Sensitive and Targeted Sequencing Technologies Several new sequencing technologies combine to provide a foundational platform for the detection and sequencing of rare mutations and rare cells with extraordinary sensitivity and accuracy.Learn more>

Broad Spectrum Anti-Bacterial Drugs Proprietary drug leads that are potential first-in-class, broad-spectrum antibiotics inhibiting both DNA gyrase and RecBCD/AddAB DNA repair enzymes. The lead compounds may have the potential to treat difficult infectious diseases such as tuberculosis and are less likely to become ineffective due to drug resistance.Learn more>